Recovery and assessment timescales in anemia extend from weeks to months. Initial post-infusion fever or cytopaenia flare (expected in some protocols) resolves within 1–2 weeks. Meaningful haematologic response — increased reticulocytes, improved haemoglobin, reduced transfusion requirement — typically emerges over 4–12 weeks. Complete blood count and reticulocyte count are typically assessed at 2, 4, 8, and 12 weeks post-infusion. Transfusion-independence, if achieved, often becomes apparent within 8–16 weeks. Some patients experience gradual improvement without discrete recovery phase; others show rapid early response followed by plateau. Ongoing haematologic monitoring continues for 12–24 months to detect late relapse.
Anemia trials represent the largest stem-cell research cohort, reflecting disease prevalence and unmet medical need. Trial outcomes vary substantially by anaemia type. In aplastic anaemia and myelodysplastic syndrome cohorts, MSC infusion has supported haematopoietic recovery, with some patients achieving transfusion-independence. In chronic kidney disease anaemia, paracrine effects of MSCs may enhance endogenous erythropoietin responsiveness. Autoimmune haemolytic anaemia trials report reduced haemolysis markers and improved haemoglobin in responsive patients. However, heterogeneous trial designs, small sample sizes, and variable control arms limit systematic comparison. Eighty-three recruiting trials suggest ongoing clinical momentum, though few have advanced to Phase 3 efficacy endpoints. Long-term haematological stability post-treatment remains incompletely characterised.
Sunt un candidat? → · Anemia: full overview → · Cost Anemie → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită